The objectives of the STREXIT 2 Project in the words of Principal Investigator and Co-Leader Dr Winan van Houdt
STREXIT 2 is part of a series of clinical trials funded by the Horizon Europe programme as part...
STREXIT2 is proposed to amend the ongoing phase III EORTC clinical trial STRASS2 investigating the added value of neoadjuvant chemotherapy before surgery for high-risk retroperitoneal sarcoma and to add an observational arm STREXIT2 that will capture real world data from patients not participating to STRASS2.
Retroperitoneal sarcomas are rare diseases refractory to treatment with dismal prognosis. Surgery is the only standard approach to primary disease. We are proposing an innovative pragmatic approach supplementing a standard phase III clinical trial with an observational cohort.
We will perform health economics analysis assessing the economic value of different treatment scenarios based on STRASS2 and STREXIT2. If successful, the outcomes of the project will define a new evidence-based standard of care for high-risk retroperitoneal sarcomas.
We are a multidisciplinary and multistakeholder consortium involving clinical oncologists, surgeons, health economists and patient representatives. The study design was successfully discussed with patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.
STREXIT 2 is part of a series of clinical trials funded by the Horizon Europe programme as part...
Over the last couple of months, we introduced the people and organisations behind the STREXIT2 Project on our...
On Sarcoma Awareness Month, the European Organisation for Research and Treatment of Cancer (EORTC) and the Syreon Research Institute are...
© The STREXIT2 Consortium 2023-2028. This project has received funding from the European Union’s HORIZON-MISS-CANCER-2022-01 under grant agreement Nº (101103843).
Copyright © 2024 All rights reserved.